CTOs on the Move

Elcelyx Therapeutics

www.elcelyx.com

 
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.elcelyx.com
  • 11995 El Camino Real Suite 305
    San Diego, CA USA 92130-2567
  • Phone: 858.876.1814

Executives

Name Title Contact Details

Funding

Elcelyx Therapeutics raised $40M on 10/01/2015

Similar Companies

Porter

Porter is an AI-driven Healthsphere that includes navigable content, a curated marketplace, coverage information, and supportive online health communities that deliver actionable insights to transform the care-at-home journey. Porter`s platform guides patients and caregivers to make informed, personalized health decisions based on their own speed, quality, and cost desires.

reportassistant

reportassistant is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Futrix

Futrix is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thomas Scientific

Thomas Scientific is a Swedesboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.